GlassScriptPhysician profile
Kim T Tran
NPI 1972710465
$1,343.76
in general payments reported to CMS, 2019-2025
20 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.19 · 2020: $12.62 · 2021: $144 · 2022: $510 · 2023: $310 · 2024: $114 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.71 | 2021-2023 | Ofev |
| Vifor Pharma, INC. | $177.97 | 2022-2023 | Veltassa |
| Medtronic, INC. | $170.43 | 2023 | Intellis Adaptivestim |
| Outset Medical INC | $109.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.66 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $82.95 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.70 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.29 | 2025 | Calquence |
| Stryker Corporation | $56.15 | 2024 | Optablate, Spinejack |
| Actelion Pharmaceuticals US, INC. | $44.09 | 2023-2025 | Opsumit, Uptravi |
| Travere Therapeutics, INC. | $42.75 | 2020-2025 | |
| Calliditas Therapeutics US INC. | $40.17 | 2022-2023 | Tarpeyo |
| Genzyme Corporation | $36.10 | 2024 | |
| Daiichi Sankyo INC. | $28.76 | 2025 | Enhertu |
| Ucb, INC. | $23.96 | 2025 | Bimzelx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.10 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $20.81 | 2025 | Ninlaro |
| Beta Bionics, INC. | $16.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $15.45 | 2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $15.21 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.